# A Study of the Safety and Efficacy of EBV Specific T-cell Lines

> **NCT02580539** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dr. Jean-Sebastien Delisle, MD, PhD** · enrollment: 12 (estimated)

## Conditions studied

- Epstein-Barr Virus Infections
- Post-Transplant Lymphoproliferative Disorder
- Lymphoma

## Interventions

- **BIOLOGICAL:** Group A
- **BIOLOGICAL:** Group B

## Key facts

- **NCT ID:** NCT02580539
- **Lead sponsor:** Dr. Jean-Sebastien Delisle, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580539, "A Study of the Safety and Efficacy of EBV Specific T-cell Lines". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02580539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*